A Phase 2, Two-Arm, Double-Blind, Multi-Center, Randomized Study of the Combination of Oral WX-671 [Wilex] Plus Capecitabine [Xeloda; Hoffman La Roche AG] vs. Capecitabine Monotherapy in First-Line Her2-Negative Metastatic Breast Cancer.

Trial Profile

A Phase 2, Two-Arm, Double-Blind, Multi-Center, Randomized Study of the Combination of Oral WX-671 [Wilex] Plus Capecitabine [Xeloda; Hoffman La Roche AG] vs. Capecitabine Monotherapy in First-Line Her2-Negative Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Upamostat (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors WILEX AG
  • Most Recent Events

    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 11 Apr 2013 Results will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO-2013) according to a WILEX media release.
    • 08 Dec 2012 Patients were recruited between August 2008 and April 2011 according to the abstract presented at the 35th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top